<DOC>
	<DOCNO>NCT00880620</DOCNO>
	<brief_summary>This study examine efficacy IPX066 compare placebo Parkinson 's disease .</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson 's Disease</brief_title>
	<detailed_description>A randomize , placebo control , fix dose , parallel arm study three dos IPX066 versus placebo . Approximately 350 subject plan randomize receive one 3 dos IPX066 , match placebo , orally order complete approximately 300 subject . Study duration approximately 30 week subject . The UPDRS primary outcome measure .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Able understand willing voluntarily sign informed consent form ( ICF ) Health Insurance Portability Accountability Act ( HIPAA ) authorization local equivalent applicable . 2 . Diagnosed idiopathic PD . 3 . LDna√Øve : defined subject expose LD catecholOmethyl transferase inhibitor 30 day exposure within 4 week prior study enrollment . 4 . If currently take anticholinergic therapy , amantadine , monoamine oxidase type B ( MAOB ) inhibitor , maintain stable regimen least 4 week prior Baseline , agree maintain stable regimen throughout study participation . 5 . Agrees use medically acceptable method contraception throughout study 1 month complete study . 6 . Able willing comply protocol , include availability schedule clinic visit telephone call . 1 . Pregnant breastfeeding . 2 . Diagnosed atypical Parkinsonism know secondary parkinsonian syndrome . 3 . Prior functional neurosurgical treatment PD procedure anticipate study participation . 4 . Use nonselective MAO inhibitor . 5 . Use dopamine agonist within 30 day prior Screening . 6 . Unable tolerate placebo regimen , Investigator 's opinion . 7 . Treatment psychosis antipsychotic . 8 . History seizure epilepsy . 9 . Active prior medical condition prior surgical procedure would interfere LD absorption . 10 . History narrowangle glaucoma . 11 . Subjects history malignant melanoma . 12 . History myocardial infarction residual atrial , nodal , ventricular arrhythmia , upper gastrointestinal hemorrhage , neuroleptic malignant syndrome . 13 . Received investigational medication 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
</DOC>